Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen

Cortellini, A. ; Parisi, A. ; Cannita, K. ; Venditti, O. ; Pavese, F. ; D'Orazio, C. ; Lanfiuti Baldi, P. ; Vicentini, V. ; Vicentini, R. ; Porzio, G. ; Verna, L. ; Ficorella, C.

England: Elsevier Ltd

Full text available

Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types

Dal Maso, L. ; Guzzinati, S. ; Buzzoni, C. ; Capocaccia, R. ; Serraino, D. ; Caldarella, A. ; Dei Tos, A.P. ; Falcini, F. ; Autelitano, M. ; Masanotti, G. ; Ferretti, S. ; Tisano, F. ; Tirelli, U. ; Crocetti, E. ; De Angelis, R. ; Virdone, S. ; Zucchetto, A. ; Gigli, A. ; Francisci, S. ; Baili, P. ; Gatta, G. ; Castaing, M. ; Zanetti, R. ; Contiero, P. ; Bidoli, E. ; Vercelli, M. ; Michiara, M. ; Federico, M. ; Senatore, G. ; Pannozzo, F. ; Vicentini, M. ; Bulatko, A. ; Pirino, D.R. ; Gentilini, M. ; Fusco, M. ; Giacomin, A. ; Fanetti, A.C. ; Cusimano, R.

Oxford: Elsevier Ltd

Full text available

Exploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]

Pilotto, S. ; Vita, E. ; Sperduti, I. ; Noia, V P Di ; Grizzi, G. ; D’Argento, E. ; Simbolo, M. ; Vicentini, C. ; Caliò, A. ; Mafficini, A. ; Carbognin, L. ; Corbo, V. ; Gkountakos, A. ; Santo, A. ; Brunelli, M. ; Martini, M. ; Scarpa, A. ; Milella, M. ; Tortora, G. ; Bria, E.

Full text available

1584P - Exploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]

Pilotto, S. ; Vita, E. ; Sperduti, I. ; Noia, V P Di ; Grizzi, G. ; D’Argento, E. ; Simbolo, M. ; Vicentini, C. ; Caliò, A. ; Mafficini, A. ; Carbognin, L. ; Corbo, V. ; Gkountakos, A. ; Santo, A. ; Brunelli, M. ; Martini, M. ; Scarpa, A. ; Milella, M. ; Tortora, G. ; Bria, E.

Elsevier Ltd

Full text available

RICTOR/PI3K/mTOR as a clinically relevant driver of poor prognosis in squamous cell lung carcinoma (SqCLC): Preliminary results of prognostic outliers according to a validated clinicopathological model

Pilotto, S. ; Simbolo, M. ; Sperduti, I. ; Novello, S. ; Vicentini, C. ; Peretti, U. ; Pedron, S. ; Milella, M. ; Mafficini, A. ; Visca, P. ; Volante, M. ; Facciolo, F. ; Santo, A. ; Infante, M. ; Carbognin, L. ; Brunelli, M. ; Chilosi, M. ; Scarpa, A. ; Tortora, G. ; Bria, E.

Elsevier Ltd

Full text available

Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model

Pilotto, S. ; Simbolo, M. ; Sperduti, I. ; Novello, S. ; Vicentini, C. ; Peretti, U. ; Pedron, S. ; Milella, M. ; Mafficini, A. ; Visca, P. ; Volante, M. ; Facciolo, F. ; Santo, A. ; Infante, M. ; Carbognin, L. ; Brunelli, M. ; Chilosi, M. ; Scarpa, A. ; Tortora, G. ; Bria, E.

Full text available

P-136Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen

Cortellini, A ; Parisi, A ; Cannita, K ; Venditti, O ; Pavese, F ; D'Orazio, C ; Lanfiuti Baldi, P ; Vicentini, V ; Vicentini, R ; Porzio, G ; Verna, L ; Ficorella, C

Oxford University Press

Full text available

1584PExploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]

Pilotto, S ; Vita, E ; Sperduti, I ; Noia, V P Di ; Grizzi, G ; D’Argento, E ; Simbolo, M ; Vicentini, C ; Caliò, A ; Mafficini, A ; Carbognin, L ; Corbo, V ; Gkountakos, A ; Santo, A ; Brunelli, M ; Martini, M ; Scarpa, A ; Milella, M ; Tortora, G ; Bria, E

Oxford University Press

Full text available